Last updated on May 2012

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.


Brief description of study

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

Detailed Study Description

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin compared with placebo, in addition to standard of care, in patients with type II diabetes mellitus and acute coronary syndrome.

Patient Inclusion Criteria:
In order to participate in this study you need to have a hgA1c level between 6.5-11.0% , and a history of ACS (acute coronary syndrome) that required hospitalization with in 15-90 days prior to randomization.

Patient Exclusion Criteria:

  • Signs of type I diabetes mellitus
  • currently receiving a glucagon- like peptide 1 for glycemic control.
  • Hemodynamically unstable cardiovascular disorder including heart failure
  • Received or is receiving dialysis
  • Patient has human immunodeficiency virus
  • Alcohol or substance abuse

Clinical Study Identifier: TX135717

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Nasra Hashmi

Coastal Multi-Specialty Research
Santa Ana, CA USA
  Connect »